Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment

Dotan Moskovich, Yael Finkelshtein, Adi Alfandari, Amit Rosemarin, Tzuri Lifschytz, Avivit Weisz, Santanu Mondal, Harinarayana Ungati, Aviva Katzav, Debora Kidron, Govindasamy Mugesh, Martin Ellis, Bernard Lerer, Osnat Ashur-Fabian*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Fingerprint

Dive into the research topics of 'Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science